HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Imipramine Hydrochloride

HCID 8228
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
113-52-0
Standard SMILES
CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl
InChIKey
XZZXIYZZBJDEEP-UHFFFAOYSA-N
Molecular formula
C19H25ClN2
Average molar mass
316.9 g/mol
Monoisotopic mass
316.1706265

Overview

Imipramine Hydrochloride is the hydrochloride salt form of imipramine, a synthetic tricyclic derivative, antidepressant Imipramine enhances monoamine neurotransmission in certain areas of the brain. It also induces sedation through histamine 1 receptor blockage; hypotension through beta-adrenergic blockage; and diverse parasympatholytic effects. Imipramine has less sedative effect than other members of its therapeutic family. It is used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. (NCI04)

Names & identifiers

Preferred name
Imipramine Hydrochloride
IUPAC
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;hydrochloride
English name
Imipramine hydrochloride
Molecular formula
C19H25ClN2
Molecular weight
316.87

Names & synonyms

Imipramine hydrochloride113-52-0Imipramine HclTofranilPresaminePryleuganPramineAntideprin hydrochlorideImipramini hydrochloridumPraminilSarimpDTXSID7040738
Show more names
g22355imidolia-pramimavateiprogendeprinoldynazinaefuranol
BKE5Q1J60UNSC-114900G-223555H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochlorideCHEBI:5882DTXCID5020738NSC1149005H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride

Database identifiers

CAS
113-52-0
PubChem CID
8228
DTXSID
DTXSID7040738
ChEMBL
CHEMBL1692
UNII
BKE5Q1J60U
EC Number
204-030-7

Properties

Computed structural propertiesFilling in

Topological polar surface area
6.5 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
4
Heavy atoms
22
Formal charge
0
Complexity
291

Experimental & physicochemical properties

Solubility>47.5 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Tricyclic

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section165.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
168 · 168-1700C
Flash point
9 ℃ · 9℃
storage temp.
2 · 2-8°C
solubility
2 O: · H2O: 50 mg/mL
form
crystalline
color
white
PH
4.2 · 4.2~5.2(100g/l,25℃)
Water Solubility
Soluble in water
λmax
260 nm · 260nm(lit.)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 92 reports by companies from 4 notifications to the ECHA C&L Inventory.

Hazard information

Regulatory InformationImipramine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Treatment · 1 item

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at anytime during this period, extended monitoring is required. (L1712)

Exposure RoutesRapidly and well absorbed after oral administration. Bioavailability is approximately 43%. Peak plasma concentrations usually attained 1 - 2 hours following oral administration. Absorption is unaffected by food.

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Exclusively metabolized by the liver. Imipramine is converted in the liver by various CYP isoenzymes (e.g. CYP1A2, CYP2D6, CYP3A4, CYP2C9) to active metabolites desipramine and 2-hydroxydesipramine. Route of Elimination: Approximately 40% of an orally administered dose is eliminated in urine within 24 hours, 70% in 72 hours. Small amounts are eliminated in feces via the biliary elimination. Half Life: Imipramine - 8-20 hours; Desipramine (active metabolite) - up to 125 hours

FDA Pharmacological Classification · 2 items

IMIPRAMINE HYDROCHLORIDE

Tricyclic Antidepressant [EPC]

MeSH Pharmacological Classification · 2 items

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Uses & manufacturing

Uses · 1 item

For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.

Related reactions

11 records
New reaction record
HRID 335046 reaction equation
HRID 335046As reactant
HRID 536784 reaction equation
HRID 536784As reactant
HRID 536785 reaction equation
HRID 536785As reactant
HRID 1484197 reaction equation
HRID 1484197As reactant
HRID 1484198 reaction equation
HRID 1484198As reactant
HRID 1664118 reaction equation
HRID 1664118As productAs reactant
HRID 2035404 reaction equation
HRID 2035404As reactant
HRID 2035405 reaction equation
HRID 2035405As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Merck
14 · 14,4920
InChI
1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H
InChIKey
XZZXIYZZBJDEEP-UHFFFAOYSA-N
SMILES
Cl[H].CN(C)CCCN1c2ccccc2CCc3ccccc13
CAS DataBase Reference
113 · 113-52-0(CAS DataBase Reference)
FDA UNII
5 Q1J60U · BKE5Q1J60U
EPA Substance Registry System
5 H-Dibenz[b,f]azepine-5-propanamine, · 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride (113-52-0)
UNSPSC Code
41116107 · 41116107
NACRES
25 · NA.25
Protein binding
95 % · 95%
Excreted unchanged in urine
5 % · 5%
Volume of distribution
31 · 31(L/kg)
Biological half-life
9 · 9-28 / -
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
300 · H300
Precautionary statements
264 · P264-P270-P301+P310-P405-P501
Hazard Codes
Xn,T,F
Risk Statements
23 · 23/25-36/38-36/37/38-22-39/23/24/25-23/24/25-11
Safety Statements
7 · 7-16-24-33-45-36-26-36/37
RIDADR
1230 · UN 1230 3/PG 2
WGK Germany
3 · 3
RTECS
1925000 · HO1925000
TSCA
TSCA listed
HS Code
2933995800 · 2933995800
Storage Class
6.1 A · 6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
2 Oral · Acute Tox. 2 Oral
Toxicity
50 in · LD50 in mice, rats (mg/kg): 400, 490 orally; 110, 90 i.p. (Tobe)
Toxicity Summary · 1 item

Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission.

Signs and Symptoms · 1 item

Antagonism of the histamine H<sub>1</sub> and &alpha;<sub>1</sub> receptors can lead to sedation and hypotension. Antimuscarinic and anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of imipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Imipramine hydrochloride

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 355 to 682 mg/kg (oral, rat).

Safety data

wgk
3
tsca
TSCA listed
rtecs
HO1925000
ridadr
UN 1230 3/PG 2
hs_code
2933995800
Toxicity
LD50 in mice, rats (mg/kg): 400, 490 orally; 110, 90 i.p. (Tobe)
risk_code
23/25-36/38-36/37/38-22-39/23/24/25-23/24/25-11
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
Xn,T,F
safety_code
7-16-24-33-45-36-26-36/37
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard statements
H300
Hazard Classifications
Acute Tox. 2 Oral
Precautionary statements
P264-P270-P301+P310-P405-P501
General Manufacturing Information
5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, hydrochloride (1:1): ACTIVE
Applications · 4 items

UsesImipramine hydrochloride is used as a serotonin uptake inhibitor. It mainly used in the treatment of major depression and enuresis (inability to control urination). It has also been evaluated for use in panic disorder.

UsesTricyclic antidepressant; inhibits the serotonin and norepinephrine transporters. Has little effect on the dopamine transporter

UsesAntidepressant;5-HT transport inhibitor

General DescriptionImipramine hydrochloride, 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine monohydrochloride(Tofranil), is the lead compound of the TCAs. It is also a closerelative of the antipsychotic phenothiazines (replace the10–11 bridge with sulfur, and the compound is the antipsychoticagent promazine). It has weaker D2 postsynaptic blockingactivity than promazine and mainly affects amines (5-HT,NE, and DA) via the transporters. As is typical of dimethylaminocompounds, anticholinergic and sedative (central H1block) effects tend to be marked. The compound per se has a tendency toward a high 5-HT-to-NE uptake block ratio andprobably can be called a serotonin transport inhibitor(SERTI). Metabolic inactivation proceeds mainly by oxidativehydroxylation in the 2-position, followed by conjugationwith glucuronic acid of the conjugate. Urinary excretion predominates(about 75%), but some biliary excretion (up to25%) can occur, probably because of the large nonpolargrouping. Oxidative hydroxylation is not as rapid or completeas that of the more nucleophilic ring phenothiazine antipsychotics;consequently, appreciable N-demethylation occurs,with a buildup of norimipramine (or desimipramine).

Upstream & downstream products

Upstream raw materials

DiphenylImipramineHexamethyleneimineSodium amideHydrochloric acidIminodibenzyl